1. Home
  2. ALT vs RPAY Comparison

ALT vs RPAY Comparison

Compare ALT & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • RPAY
  • Stock Information
  • Founded
  • ALT 1997
  • RPAY 2006
  • Country
  • ALT United States
  • RPAY United States
  • Employees
  • ALT N/A
  • RPAY N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • RPAY Business Services
  • Sector
  • ALT Health Care
  • RPAY Consumer Discretionary
  • Exchange
  • ALT Nasdaq
  • RPAY Nasdaq
  • Market Cap
  • ALT 397.4M
  • RPAY 387.2M
  • IPO Year
  • ALT N/A
  • RPAY N/A
  • Fundamental
  • Price
  • ALT $4.19
  • RPAY $4.79
  • Analyst Decision
  • ALT Strong Buy
  • RPAY Buy
  • Analyst Count
  • ALT 6
  • RPAY 9
  • Target Price
  • ALT $18.20
  • RPAY $8.06
  • AVG Volume (30 Days)
  • ALT 11.7M
  • RPAY 1.3M
  • Earning Date
  • ALT 08-07-2025
  • RPAY 08-07-2025
  • Dividend Yield
  • ALT N/A
  • RPAY N/A
  • EPS Growth
  • ALT N/A
  • RPAY N/A
  • EPS
  • ALT N/A
  • RPAY N/A
  • Revenue
  • ALT $20,000.00
  • RPAY $309,647,000.00
  • Revenue This Year
  • ALT N/A
  • RPAY N/A
  • Revenue Next Year
  • ALT $1,557,547.90
  • RPAY $8.40
  • P/E Ratio
  • ALT N/A
  • RPAY N/A
  • Revenue Growth
  • ALT N/A
  • RPAY 2.26
  • 52 Week Low
  • ALT $2.90
  • RPAY $3.59
  • 52 Week High
  • ALT $11.16
  • RPAY $10.16
  • Technical
  • Relative Strength Index (RSI)
  • ALT 39.67
  • RPAY 48.67
  • Support Level
  • ALT $4.33
  • RPAY $4.84
  • Resistance Level
  • ALT $4.79
  • RPAY $5.12
  • Average True Range (ATR)
  • ALT 0.52
  • RPAY 0.16
  • MACD
  • ALT -0.16
  • RPAY -0.00
  • Stochastic Oscillator
  • ALT 26.92
  • RPAY 42.61

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About RPAY Repay Holdings Corporation

Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.

Share on Social Networks: